Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2021 | KEYNOTE-062: pembrolizumab vs. chemo in 1L advanced gastric cancer

Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, outlines the results of KEYNOTE-062, a Phase II randomized study investigating the efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy versus chemotherapy alone in patients with first-line (1L) advanced gastric cancer. The findings suggest that among patients with untreated, advanced gastric cancer, pembrolizumab was non-inferior to chemotherapy, with fewer adverse events observed, however, pembrolizumab or pembrolizumab plus chemotherapy was not superior to chemotherapy. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).